Merck: encouraging results in prostate cancer
(CercleFinance.com) - AstraZeneca and Merck today announced positive results from the Phase 3 PROpel trial.
LYNPARZA (olaparib) in combination with Abiraterone significantly delayed disease progression in patients regardless of biomarker status in PROpel Phase-3 trial in first-line metastatic Castration-Resistant Prostate Cancer (mCRPC).
At a planned interim analysis, the Independent Data Monitoring Committee concluded that the trial met the primary endpoint of rPFS in men with mCRPC who had not received treatment in the first-line setting, including new hormonal agents (NHAs) or chemotherapy.
The trial also showed a trend at this interim analysis towards improved overall survival (OS).
Copyright (c) 2021 CercleFinance.com. All rights reserved.
LYNPARZA (olaparib) in combination with Abiraterone significantly delayed disease progression in patients regardless of biomarker status in PROpel Phase-3 trial in first-line metastatic Castration-Resistant Prostate Cancer (mCRPC).
At a planned interim analysis, the Independent Data Monitoring Committee concluded that the trial met the primary endpoint of rPFS in men with mCRPC who had not received treatment in the first-line setting, including new hormonal agents (NHAs) or chemotherapy.
The trial also showed a trend at this interim analysis towards improved overall survival (OS).
Copyright (c) 2021 CercleFinance.com. All rights reserved.